Sunshine Biopharma Inc. (SBFM) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders held by Sunshine Biopharma Inc. on December 10, 2024. The company is incorporated in Colorado and trades on The Nasdaq Stock Market LLC under the symbols SBFM (Common Stock) and SBFMW (Warrants).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Corporate Actions
The primary event reported is the outcome of the annual stockholder vote. Key actions include:
- Election of Directors: Five individuals were elected to the Board of Directors to serve until the next annual meeting: Dr. Steve N. Slilaty, Dr. Abderrazzak Merzouki, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller.
- Auditor Ratification: Stockholders ratified the appointment of Bush & Associates CPA LLC as the independent registered public accounting firm for 2024.
Voting Results
| Proposal | For | Against/Withheld | Abstain |
|---|---|---|---|
| Election of Directors (All 5 Candidates) | ~130.07M - 130.08M | ~36k - 49k (Withheld) | 0 |
| Ratification of Auditor | 130,089,305 | 15,456 | 11,725 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the continued tenure of the newly elected board members, particularly Dr. Steve N. Slilaty (CEO).
- Confirm the engagement of Bush & Associates CPA LLC for the 2024 audit cycle.
- Note the high level of support for director elections, with over 130 million votes cast "For" each candidate and zero broker non-votes.